|
|
|
| Effect of Levodopa combined with Carbaratin on Cognitive Impairment, Motor Function and Balance Function in Parkinson's Disease |
| MI Wan-jun, CHANG Lin |
| Department of Neurology, Weinan Central Hospital, Shaanxi Weinan, 714300, China |
|
|
|
|
Abstract 【Objective】 To investigate the effect of levodopa combined with carbaratin on cognitive impairment, motor function and balance function in Parkinson's disease. 【Methods】 A total of 86 PD patients treated in our hospital from June 2016 to August 2018 were selected as the study subjects and randomly divided into control and observation groups by random number table method, with 43 patients in each group.Patients in the control group were treated with levodopa, and patients in the observation group were treated with levodopa combined with carbaratin continuously for 6 months.The time to clinical improvement, cognitive, motor, and balance function scores, tendon reflexes, muscle tone, and muscle spasms scores, and adverse effects were compared between the two groups. 【Results】 After treatment, patients in the observation group had significantly less time to improvement in clinical symptoms (myotonia, bradykinesia, resting tremor and postural walking disorders) than those in the control group (P<0.05); the Alzheimer's disease assessment scale cognitive subscale (ADAS COG) and Unified Parkinson's disease assessment scale Part Ⅲ(UPDRS Ⅲ) scores were reduced in both groups, and were significantly lower in the observation group than in the control group (P<0.05);Berg Balance Function Scale scores were significantly higher in both groups, and significantly higher in the observation group (P<0.05);Tendon reflexes, muscle tone, and muscle spasticity scores were reduced in both groups, and were significantly lower in the observation group than that in the control group (P<0.05);the incidence of adverse events in the observation group was 11.61%, which was significantly lower than that in the control group (32.54%)(P<0.05).【Conclusion】 The use of levodopa plus carbaratinin patients with Parkinson's disease has definite efficacy, can significantly improve patients' cognitive impairment, motor function, and balance function, and the safety profile is also high, which warrants clinical promotion.
|
|
Received: 15 October 2019
|
|
|
|
|
|
[1] 许玉珉,黑赏艳,章时杰,等.中西医结合治疗帕金森病睡眠障碍随机对照试验的Meta分析[J].广州中医药大学学报,2018,35(3):540-548.
[2] 张勇,黄黛.帕金森应用左旋多巴联合普拉克索治疗的临床疗效观察[J].中国医药指南,2015,13(24):147-148.
[3] 杨仁妹.普拉克索联合左旋多巴用于帕金森病患者的疗效分析[J].中国药物经济学,2017,12(9):60-62.
[4] 杨盛贤,方芳,刘波,等.左旋多巴对老年帕金森病患者认知功能及血浆Hcy、维生素B12、叶酸水平的影响[J].国际精神病学杂志,2017,44(3):484-487.
[5] 李振光,李刚,于占彩,等.卡巴拉汀对帕金森病认知功能障碍及跌倒的影响[J].中华临床医师杂志,2015,9(19):3549-3553.
[6] 朱冬梅, 熊学智.左旋多巴联合卡巴拉汀治疗对帕金森病患者肌强直及多巴转运体的影响[J].医学临床研究,2018,35(5):876-878.
[7] Britto HMJS, Mendes LDA, Moreno CC,et al. Correlation between balance, speed, and walking ability in individuals with chronic hemiparesis[J].Fisioterapia em Movimento,2016, 29(1):87-94.
[8] 高岩,赵亚明.卡巴拉汀联合左旋多巴治疗帕金森病的临床研究[J].现代药物与临床,2018, 33(5):233-237.
[9] 刘疏影,陈彪.帕金森病流行现状[J].中国现代神经疾病杂志,2016,16(2):98-101.
[10] 张妙华.普拉克索治疗帕金森病临床疗效和安全性研究[J].中国实用神经疾病志,2015, 18(1):117-118.
[11] 陈宗元,黄春丽,官检发,等.帕金森病的流行病学、发病机制及药物的研究进展[J].海峡药学,2018,30(3):48-50.
[12] 朱灿敏,肖家平,张弦,等.听觉诱发电位对早期帕金森患者药物治疗后认知功能受损的评估[J].重庆医学,2017,46(23):3266-3269.
[13] 李晋,贺敬敬,易蕊,等.左旋多巴/卡比多巴联合恩他卡朋治疗帕金森病的临床研究[J].现代生物医学进展,2016,16(3):504-506.
[14] 孙绍武.普拉克索联合左旋多巴对晚期帕金森病患者临床症状及负性情绪的影响[J].中国实用神经疾病杂志,2017,20(4):118-120.
[15] 熊焰.分析探讨左旋多巴联合普拉克索治疗帕金森的有效性及安全性[J].中国实用医药, 2014,9(12):145-146.
[16] 张光妍,陈文荣,凌亚兴,等.胆碱酯酶抑制剂联合抗精神病药对老年帕金森患者高级认知功能的影响[J].白求恩医学杂志,2016,14(6):718-720. |
|
|
|
2021, Vol. 38 
